The Makary Exit: When 'Difficulty' Masks Structural Accountability Gaps

The Official Narrative

Dr. Marty Makary's tenure as Commissioner of the Food and Drug Administration has concluded, with administration officials and media reporting characterizing it as ending with "difficulty." The framing is notable for its vagueness: no specific constitutional violation is alleged, no statutory breach is named, and no concrete mechanism of accountability is invoked. The narrative presents a departure shrouded in administrative euphemism—a transition marked by unspecified challenges rather than documented institutional failures or achievements.

This opacity is not incidental. It reflects a broader pattern in which the performance of agency heads is evaluated through political optics rather than the statutory framework that governs their authority and obligations.

The Constitutional and Statutory Framework

The FDA Commissioner operates under Title 21 of the United States Code, specifically 21 U.S.C. § 393, which establishes the position as serving at the pleasure of the President. The Commissioner's authority derives from the Federal Food, Drug, and Cosmetic Act (FFDCA), which mandates specific duties: ensuring the safety and efficacy of drugs, biologics, and medical devices; enforcing food safety standards; and protecting public health through regulatory oversight.

The Administrative Procedure Act of 1946 (5 U.S.C. § 551 et seq.) governs how the FDA must conduct its rulemaking and enforcement activities. It requires notice-and-comment procedures for regulations, mandates that agency actions not be "arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law," and provides for judicial review of agency decisions.

The Federal Vacancies Reform Act of 1998 (5 U.S.C. § 3345 et seq.) establishes the procedures for filling executive branch vacancies, including time limits on acting officials and requirements for Senate confirmation of permanent appointees.

These are not abstract principles. They are the operational manual for how the FDA Commissioner's performance should be measured: Did the agency fulfill its statutory mandates? Were its regulatory decisions procedurally sound and substantively justified? Did the Commissioner comply with congressional oversight requirements?

What the Record Shows

The "difficulty" framing provides no answer to these questions. It does not identify whether:

• Any FDA rulemaking during Makary's tenure was successfully challenged under the APA for being arbitrary or capricious;
• The agency failed to meet statutory deadlines for drug or device approvals;
• Congressional appropriations for FDA operations were mismanaged or unspent;
• The Commissioner refused to comply with lawful congressional subpoenas or oversight requests;
• Specific public health outcomes deteriorated under measurable statutory benchmarks.

The absence of these specifics is structurally significant. If Makary's tenure involved failures of statutory compliance, those failures have legal remedies: judicial review under the APA, congressional hearings and potential funding restrictions, or Presidential removal for cause. If the "difficulty" instead refers to policy disagreements—disputes over regulatory philosophy, the pace of drug approvals, or the balance between innovation and safety—then the appropriate forum is the democratic process, not administrative euphemism.

The gap between "difficulty" and documented statutory breach reveals a troubling institutional pattern: agency leadership is evaluated not by the legal framework that governs its authority, but by political palatability and media narrative.

Historical Precedent: When Commissioners Actually Failed

The FDA has a documented history of leadership crises that provide a useful contrast. In 1990, Dr. David Kessler was appointed Commissioner and immediately faced congressional scrutiny over the agency's handling of generic drug approvals, which had been compromised by a bribery scandal. Kessler's response was not characterized by vague "difficulty"—it involved specific reforms, criminal prosecutions, and measurable improvements in agency integrity.

In 2006, Dr. Andrew von Eschenbach faced Senate confirmation challenges over concerns about the agency's delay in approving over-the-counter emergency contraception. The dispute was substantive and specific: Had the FDA violated its own scientific review process for political reasons? The question was litigated in federal court (Tummino v. Torti, 603 F. Supp. 2d 519 (E.D.N.Y. 2009)), and the agency was found to have acted improperly.

These cases demonstrate what structural accountability looks like: specific allegations, formal mechanisms of review, and documented outcomes. The Makary "difficulty" narrative contains none of these elements.

The Mechanism Gap

The Constitution provides clear tools for holding executive officials accountable. Article II, Section 4 establishes impeachment for "high Crimes and Misdemeanors." The Appointments Clause (Article II, Section 2) requires Senate confirmation, creating a point of legislative vetting. The Take Care Clause (Article II, Section 3) obligates the President to ensure laws are faithfully executed, and by extension, empowers removal of officials who fail to do so.

Congress possesses the power of the purse (Article I, Section 9) and investigative authority through committees. The judiciary reviews agency actions under the APA and other statutory frameworks.

If Makary's tenure ended with "difficulty," which of these mechanisms was invoked? If none, what does that reveal about the nature of the difficulty? The absence of formal accountability measures suggests one of two possibilities: either no statutory violation occurred, making the "difficulty" a matter of political preference rather than legal deficiency; or statutory violations did occur, but the institutional mechanisms designed to address them were not engaged.

Both possibilities are troubling. The first represents the substitution of narrative for legal standard. The second represents the abandonment of structural accountability in favor of quiet exits.

What Structural Accountability Requires

If Dr. Makary's tenure involved failures of statutory duty, the appropriate response is not euphemistic departure but documented review: congressional hearings examining specific agency actions, judicial review of contested rulemakings, or Inspector General investigations into compliance failures. If no such failures occurred, then the "difficulty" framing is itself a form of institutional misdirection—an attempt to delegitimize policy decisions through innuendo rather than substantive critique.

The constitutional framework does not recognize "difficulty" as a legal standard. It recognizes statutory compliance, procedural regularity, and fidelity to enacted law. The gap between these standards and the current narrative is not a semantic quibble. It is a structural erosion of how agency accountability is supposed to function in a system of separated powers.

The FDA Commissioner is not a political appointee in the sense of serving at the whim of popular opinion. The position exists to execute specific statutory mandates enacted by Congress. When that execution is characterized as ending with "difficulty" rather than assessed against the legal duties imposed by statute, the result is not accountability—it is its opposite.